The human T cell immune response to Epstein-Barr virus

Area of Science:

• Virology
• Immunology
• Oncology

Background:

• Epstein-Barr virus (EBV), a gamma-herpes virus, infects over 95% of adults, establishing lifelong latent infections.
• While EBV has oncogenic potential, most infected individuals control associated malignancies through robust immune responses.
• EBV utilizes viral latency to ensure persistence despite immune surveillance.

Purpose of the Study:

• To review and characterize T cell-mediated immune responses against Epstein-Barr virus.
• To highlight the current understanding of CD8 and CD4 T cell epitope specificity in EBV infection.
• To underscore the importance of T cell response knowledge for developing EBV-targeted immunotherapies.

Main Methods:

• Literature review of studies characterizing T cell responses to EBV.
• Analysis of data on CD8 T cell epitope focus on early lytic antigens.
• Examination of recent findings on CD4 T cell involvement in controlling EBV lytic and latent cycles.

Main Results:

• CD8 T cell responses against EBV are well-defined and primarily target early lytic viral antigens.
• Knowledge regarding CD4 T cell epitopes is less extensive due to the smaller CD4 T cell compartment size.
• Emerging evidence demonstrates that specific CD4+ T cells can effectively control both lytic and latent phases of EBV infection.

Conclusions:

• A comprehensive understanding of T cell immunity against EBV is crucial for advancing therapeutic strategies.
• Targeting specific T cell responses, including both CD8 and CD4 T cells, holds promise for treating EBV-associated diseases.
• Further research into CD4 T cell epitopes is warranted to fully elucidate their role in EBV control and immunotherapy development.